VERZENIO (Eli Lilly Australia Pty Ltd)
Early Breast Cancer
VERZENIO (tablet) in combination with endocrine therapy is now also indicated for the adjuvant treatment of patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node-positive early breast cancer at high risk of recurrence.
In pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.